Abstract
This editorial refers to “Reperfusion therapy for ST-elevation acute myocardial infarction in Eastern Europe: the ISACS-TC registry”, by E. Cenko et al ., on page 45. Reperfusion therapy, either by intravenous fibrinolysis or percutaneous coronary intervention (PCI), is the cornerstone of the management of ST-elevation myocardial infarction (STEMI).1 Randomized data have demonstrated its effectiveness in reducing mortality and morbidity, and the benefit is all the greater when it is performed early.2,3 As such, coronary reperfusion for STEMI performed within a short time frame is recommended and its timely implementation used as an indicator of quality of care.4 The estimated times to reperfusion also contribute largely to the choice of reperfusion strategy, with primary PCI being the technique of choice except if it is estimated that it cannot be performed within 120 min.1 Despite this, many patients fail to receive guideline-indicated therapies for STEMI and the proportion who do varies geographically.5 Addressing the variation in STEMI care will help reduce the substantial difference in mortality rates from cardiovascular disease between European countries.6 The choice of reperfusion strategy and the ability to … [↵][1]*Corresponding author. Tel: +44 01133438916, Email: c.p.gale{at}leeds.ac.uk [1]: #xref-corresp-1-1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European heart journal. Quality of care & clinical outcomes
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
